口服降压方案(硝苯地平缓释剂、拉贝洛尔和甲基多巴)治疗妊娠期严重高血压:一项开放标签随机对照试验
该多中心、平行组、开放标签随机对照试验在印度那格浦尔两家公立医院比较口服硝苯地平缓释剂、拉贝洛尔和甲基多巴治疗妊娠期严重高血压的疗效与安全性。894名孕妇随机分组,硝苯地平组主要结局(6小时内血压控制且无不良结局)达成率显著高于甲基多巴组(84% vs 76%,p=0.03),但与拉贝洛尔组无显著差异。作者结论认为三种口服药均为低资源环境下的可行初始选择。
要点
- 硝苯地平组主要结局达成率显著高于甲基多巴组(84% vs 76%,p=0.03)。
- 硝苯地平组与拉贝洛尔组主要结局无显著差异(84% vs 77%,p=0.05)。
- 拉贝洛尔组与甲基多巴组主要结局无显著差异(p=0.80)。
核心结论
- 所有口服降压药均使多数孕妇血压降至参考范围。
- 单药使用时,硝苯地平缓释剂的主要结局达成频率高于拉贝洛尔或甲基多巴。
- 甲基多巴、硝苯地平和拉贝洛尔三种口服药均为低资源环境下治疗严重高血压的可行初始选择。
研究设计与样本
- 多中心、平行组、开放标签、随机对照试验,在印度那格浦尔两家公立医院进行。
- 纳入年龄至少18岁、胎儿孕龄至少28周、因严重高血压(收缩压≥160 mm Hg或舒张压≥110 mm Hg)需药物降压且能口服药物的孕妇。
- 随机分配至口服硝苯地平10 mg、口服拉贝洛尔200 mg(两者每小时给药,血压持续升高时可递增剂量)或甲基多巴1000 mg(单次给药,不递增剂量)。
- 因各组剂量递增方案不同,无法对参与者、研究者和照护者设盲。
- 2015年4月1日至2017年8月21日筛查2307名女性,894名(39%)随机分组并纳入意向性治疗分析:硝苯地平组298名(33%)、拉贝洛尔组295名(33%)、甲基多巴组301名(33%)。
主要发现
- 主要结局(6小时内血压控制在收缩压120-150 mm Hg且舒张压70-100 mm Hg,无不良结局)在硝苯地平组显著高于甲基多巴组(249/298 [84%] vs 230/301 [76%],p=0.03)。
- 主要结局在硝苯地平组与拉贝洛尔组之间无显著差异(249/298 [84%] vs 228/295 [77%],p=0.05)。
- 主要结局在拉贝洛尔组与甲基多巴组之间无显著差异(p=0.80)。
- 研究期间报告7例严重不良事件(占活产的1%):拉贝洛尔组1名(<1%)女性发生产时抽搐,6名(1%)新生儿死亡(硝苯地平组1名[<1%],拉贝洛尔组2名[1%],甲基多巴组3名[1%])。
- 无任何活产发生超过1例不良事件。
临床怎么用
- 作者结论认为,甲基多巴、硝苯地平和拉贝洛尔三种口服药均为低资源环境下治疗妊娠期严重高血压的可行初始选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hypertension is the most common medical disorder in pregnancy, complicating one in ten pregnancies. Treatment of severely increased blood pressure is widely recommended to reduce the risk for maternal complications. Regimens for the acute treatment of severe hypertension typically include intravenous medications. Although effective, these drugs require venous access and careful fetal monitoring and might not be feasible in busy or low-resource environments. We therefore aimed to compare the efficacy and safety of three oral drugs, labetalol, nifedipine retard, and methyldopa for the management of severe hypertension in pregnancy. METHODS: In this multicentre, parallel-group, open-label, randomised controlled trial, we compared these oral antihypertensives in two public hospitals in Nagpur, India. Pregnant women were eligible for the trial if they were aged at least 18 years; they were pregnant with fetuses that had reached a gestational age of at least 28 weeks; they required pharmacological blood pressure control for severe hypertension (systolic blood pressure ≥160 mm Hg or diastolic blood pressure ≥110 mm Hg); and were able to swallow oral medications. Women were randomly assigned to receive 10 mg oral nifedipine, 200 mg oral labetalol (hourly, in both of which the dose could be escalated if hypertension was maintained), or 1000 mg methyldopa (a single dose, without dose escalation). Masking of participants, study investigators, and care providers to group allocation was not possible because of different escalation protocols in the study groups. The primary outcome was blood pressure control (defined as 120-150 mm Hg systolic blood pressure and 70-100 mm Hg diastolic blood pressure) within 6 h with no adverse outcomes. This study is registered with ClinicalTrials.gov, number NCT01912677, and the Clinical Trial Registry, India, number ctri/2013/08/003866. FINDINGS: Between April 1, 2015, and Aug 21, 2017, we screened 2307 women for their inclusion in the study. We excluded 1413 (61%) women who were ineligible, declined to participate, had impending eclampsia, were in active labour, or had a combination of these factors. 11 (4%) women in the nifedipine group, ten (3%) women in the labetalol group, and 11 (4%) women in the methyldopa group were ineligible for treatment (because they had only one qualifying blood pressure measurement) or had treatment stopped (because of delivery or transfer elsewhere). 894 (39%) women were randomly assigned to a treatment group and were included in the intention-to-treat analysis: 298 (33%) women were assigned to receive nifedipine, 295 (33%) women were assigned to receive labetalol, and 301 (33%) women were assigned to receive methyldopa. The primary outcome was significantly more common in women in the nifedipine group than in those in the methyldopa group (249 [84%] women vs 230 [76%] women; p=0·03). However, the primary outcome did not differ between the nifedipine and labetalol groups (249 [84%] women vs 228 [77%] women; p=0·05) or the labetalol and methyldopa groups (p=0·80). Seven serious adverse events (1% of births) were reported during the study: one (<1%) woman in the labetalol group had an intrapartum seizure and six (1%) neonates (one [<1%] neonate in the nifedipine group, two [1%] neonates in the labetalol group, and three [1%] neonates in the methyldopa group) were stillborn. No birth had more than one adverse event. INTERPRETATION: All oral antihypertensives reduced blood pressure to the reference range in most women. As single drugs, nifedipine retard use resulted in a greater frequency of primary outcome attainment than labetalol or methyldopa use. All three oral drugs-methyldopa, nifedipine, and labetalol-are viable initial options for treating severe hypertension in low-resource settings. FUNDING: PREEMPT (University of British Columbia, Vancouver, BC, Canada; grantee of Bill & Melinda Gates Foundation).
引用
- Easterling T, Mundle S, Bracken H, et al. Oral antihypertensive regimens (nifedipine retard, labetalol, and methyldopa) for management of severe hypertension in pregnancy: an open-label, randomised controlled trial. Lancet. 2019. PMID: 31378394. doi:10.1016/S0140-6736(19)31282-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。